About Kaytee Bio
Kaytee Bio, Co.&Ltd. is a biotech company incorporated and operating in Japan. We aim at overcoming diseases by developing and applying brand new diagnostic technology and drugs. We have developed a differentiated technology using short-talin to diagnose and treat RA. Our patent-protected technology allows exact diagnosis of RA at the early stage and monitoring of RA treatment. Another our powerful technology is the prediction of biologics treatment of RA based on the baseline blood ADAMTS5 mRNA expression. Efficacy of infliximab, etanercept, adalimumab, tocilizumab, and abatacept can be predictive using the “BiologicMate®” of this ADAMTS5 system. We’ve discovered the short-talin was expressed specifically in the peripheral blood obtained from RA patients. This short-talin has been thought to induce the activation and extra-vascular migration of T cells followed by the bone destruction with cytokine production. The new therapeutic procedures have been developed based on the research that the regulation of this short-talin is the key of RA treatment.
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature
CEO & Co-Founder, Zapnito
Managing Director, Thoroughly Good Consulting